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ABSTRACT
Background and Aims Opioid maintenance treatment (OMT) is recommended to opioid-dependent females during
pregnancy. However, it is not clear which medication should be preferred. We aimed to compare neonatal outcomes after
prenatal exposure to methadone (M) and buprenorphine (B) in two European countries. Design Nation-wide
register-based cohort study using personalized IDs assigned to all citizens for data linkage. Setting The Czech Republic
(2000–14) and Norway (2004–13). [Correction added after online publication on 26 April 2018: The Czech Republic
(2000–04) corrected to (2000–14).] Participants Opioid-dependent pregnant Czech (n = 333) and Norwegian
(n = 235) women in OMT who received either B or M during pregnancy and their newborns.Measurements We linked
data fromhealth registries to identify the neonatal outcomes: gestational age, preterm birth, birth weight, length and head
circumference, small for gestational age, miscarriages and stillbirth, neonatal abstinence syndrome (NAS) and Apgar
score. We performed multivariate linear regression and binary logistic regression to explore the associations between M
and B exposure and outcomes. Regression coefficient (β) and odds ratio (OR) were computed. Findings Most neonatal
outcomes were more favourable after exposure to B compared with M, but none of the differences was statistically signif-
icant. For instance, in the multivariate analysis, birth weight was β = 111.6 g [95% confidence interval (CI) = 10.5 to
233.6 and β=83.1 g, 95% CI =100.8 to 267.0] higher after B exposure in the Czech Republic andNorway, respectively.
Adjusted ORof NAS for B compared withMwas 0.94 (95% CI = 0.46–1.92) in the Norwegian cohort. Conclusions Two
national cohorts of women receiving opioid maintenance treatment during pregnancy showed small but not statistically
significant differences in neonatal outcomes in favour of buprenorphine compared with methadone.
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INTRODUCTION
Pregnant women with opioid dependence, according to the
World Health Organization (WHO) guidelines for
identification and management of substance use and
substance use disorders in pregnancy, should be advised to
continue or commence pharmacotherapywith eithermeth-
adone or buprenorphine [1,2]. Such pharmacotherapy
combined with psychosocial support is often called opioid
maintenance treatment (OMT). However, while WHO
strongly recommends OMT during pregnancy, the same
guidelines underscore that the quality of the evidence
behind this recommendation is, to date, very low.
The most used medications for OMT are methadone
(M), and buprenorphine (B), alone or in combination with
naloxone (BN). M and B are both long-acting opioid
agonists, but differ somewhat with respect to pharmaco-
logical properties [3]. While the WHO guidelines
recommend M for pregnant opioid-dependent women,
national recommendations for this patient group might
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differ, and in some countries B is recommended as the OMT
drug of choice [4,5]. In the United States, both M and B are
considered as treatment options for pregnant women [6].
The first studies, in the 1970s, compared neonatal
outcomes of children born to opioid-dependent women
who received M treatment to that of children born to
pregnant women using heroin [7–9]. Except for more
severe neonatal abstinence syndrome (NAS), children
exposed to M had better neonatal outcomes than children
exposed to heroin but worse than children born tomothers
in the general population [7]. B was approved as an OMT
drug in 2000 in some European countries. In contrast to
M, which is a full agonist, B is a partial agonist [10]. Thus,
B may not be as good choice as M to treat themost severely
addicted patients.
Two recently published systematic reviews and meta-
analyses reported that prenatal exposure to B gave more
favourable neonatal outcomes compared to M exposure
[11,12]. However, in one study the authors also performed
simulation analysis, suggesting that confounding by indi-
cation could explain some of the more favourable effects
of B, and the authors stated that more evidence is needed
to guide treatment choices [11].
Most previous studies of M versus B treatment during
pregnancy were based on small samples [13–17]; some
were not representative of the entire population of preg-
nant women who receive OMT [11,12], and many were
based mainly on urban populations [18]. In contrast to
most countries, both the Czech Republic and Norway have
nation-wide health registries that use personalized identifi-
cation number for all citizens; thismakes linkage of registry
data on individual and family levels possible [19].
Employing registry data allows us to study large unselected
populations of pregnant OMT women from countries with
different socio-economic and treatment settings.
Our aim was to compare neonatal outcomes from pre-





M became available for pregnant women at one treatment
facility in 1997 [20], B in 2000 and BN in 2008 [21]. OMT
treatment facilities have expanded gradually, from six facil-
ities in 2000 [22] to 63 facilities in 2015. Of these, 13were
methadone centres providing M and B/BN; the rest provide
B/BN only [23].
M is provided at OMT clinics only, but B and BN are
available in pharmacies and may be prescribed by any phy-
sician [24]. M is provided free of charge at clinics, while B
and BN is typically paid fully by the patients.
Norway
OMT became available nation-wide in 1998, first with M
and later with B (2000) and BN (2007) [25]. M was rec-
ommended early as the first choice but, from 2005, B has
been recommended as the first-line drug. OMT is organized
through regional centres under the specialist health-care
service, and to receive OMT patients must be included in
the national OMT programme. OMT is free of charge. For
most patients contact with specialist health care is ambula-
tory, and most pregnant women in OMT receive their OMT
medication at pharmacies [26].
Health-care providers are obliged by law to report use of
illicit drugs during pregnancy [27]. Repeated use may
result in the woman being detained, with or without her
consent, at clinics that specialize in treating pregnant
women with substance use problems [28].
Data sources
We provide a short description of the registries used in this
study; a more detailed description is provided elsewhere
[19,26].
Czech Republic
National Register of Reproduction Health (NRRH). The
NRRH have several subregistries, including the mothers
at childbirth registry and the registry of newborns. The first
includes information about the mothers during pregnancy,
such as demographic and socio-economic information,
information about alcohol, tobacco and illegal drug use
during pregnancy and information about delivery. The lat-
ter includes information about the neonate, such as birth
parameters, congenital malformations and death [29].
National Register of Addiction Treatment (NRAT). The
NRAT includes information concerning patients who
receive opioid maintenance treatment, e.g. date of initia-
tion and termination of treatment and type of OMT drug
[30,31].
Physicians are obliged by law to report data to NRRH
and NRAT.
Norway
Medical Birth Registry of Norway (MBRN). MBRN is based
on compulsory notification of every birth or late abortion
from physicians or midwives attending the birth. The
MBRN includes information concerning all births and late
abortions from the 12th gestational week and onwards,
and includes information concerning pregnancy and
delivery; the neonate (gestational age, birth parameters,
NAS, congenital malformations); demographic and socio-
economic background of mothers; and also maternal
tobacco smoking during pregnancy.
1287
© 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction, 113, 1286–1294
Norwegian Prescription Database (NorPD). The NorPD
includes information about all prescription drugs,
including OMT drugs, dispensed at pharmacies to patients
in ambulatory care. The drugs are classified according to
the Anatomical Therapeutic Chemical (ATC) classification
system [32]. Pharmacies are obliged by law to forward
prescription data to NorPD.
Statistics Norway (SSB). From Statistics Norway we in-
cluded information about maternal education. Educational
institutions are obliged to report completed education on
an individual level to SSB.
Linkage of registry data
Linkage of data between the registries was based on the
personal identification numbers assigned to all individuals
in the Czech Republic and Norway [19].
Study population and study period
The study population consisted of pregnant women in
OMT and their children born during the study period;
2000–14 in the Czech Republic and 2004–13 in Norway.
Exposure to OMT drugs during pregnancy
Only M, B and BN are used as pharmacotherapy in OMT in
the Czech Republic and Norway.
In the Czech Republic, data from the NRAT were used
to identify which women were in OMT and, if so, which
OMT drug they received.
In Norway, we used NorPD data to identify whether the
women had used M (ATC code N07 BC02), B (N07 BC01)
or BN (N07 BC51). Women who were dispensed OMT
drugs from a pharmacy at least once during pregnancy
were defined as using OMT drugs during pregnancy. More
than 95% of all OMT women receive more than one
prescription during pregnancy.
Some women switch from one substitution drug to
another during pregnancy. There were no such cases in
the Czech sample. In the Norwegian sample, women who
switched between M and B (n = 1) during pregnancy were
assigned into the M group; women who switched between
BN and B (n = 29) were assigned into the BN group.
Outcomes
Neonatal outcomes were identified in the NRRH in the
Czech data and in the MBRN in the Norwegian data.
Outcomes included: gestational age (based mainly on
ultrasound examination or, if missing, the first day of the
last menstrual period), preterm birth (< 37 weeks of
gestation), anthropometric data (birth weight, length
and head circumference), small for gestational age (SGA)
[33], miscarriage (death of a fetus between gestational
weeks 12 and 22), stillbirth (death of a fetus in gestational
week 22 or later), NAS and Apgar scores < 7 at 1 and
5 minutes.
Other variables
We obtained information on socio-demographic variables,
drug use and tobacco smoking from the NRRH in the
Czech Republic and from the MBRN and Statistics
Norway in Norway.
Analysis strategy and statistics
First, we analysed socio-demographic background and
substance use during pregnancy for women who received
pharmacotherapy with M, B or BN in the Czech Republic
and Norway, respectively. Confidence intervals for
proportions were calculated using the continuity-corrected
score interval method [34].
Next, we presented neonatal outcomes, restricted to
singleton births in both countries. Anthropometric data
(except SGA) were restricted to term births (≥ 37
gestational weeks). Gestational age, SGA, NAS and Apgar
scores were restricted to live births.
To control for relevant background characteristics, we
performed linear regression for continuous dependent
variables and binary logistic regression for categorical
dependent variables.We adjusted for maternal age, marital
status, education and tobacco smoking during pregnancy.
We compared B to M, using M as the reference group.
Unadjusted analyses in Norway were performed both in
the total sample and in a sample restricted to the same
study sample, as in the adjusted analysis.
Some of the neonatal outcomes were infrequent, and
we only performed multivariate analysis of outcomes
observed in more than four individuals. Statistical signifi-
cance level was set to 0.05.
Statistical analyses were conducted using SPSS for
Windows version 21.
Ethics
The study was approved by the Institutional Review Board
of the General University Hospital in Prague
(IRB00002705) and the Regional Committees for Medical
and Health Research Ethics (REK, AE: 2012–222) and the
Norwegian Data Inspectorate.
RESULTS
Background characteristics of women in OMT
A total number of 333 and 235 women used OMT drugs
during pregnancy in the Czech Republic and Norway, re-
spectively. Tables 1 and 2 illustrate background character-
istics of pregnant women in OMT in the Czech Republic
and Norway. In both countries, the main difference
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between the M and B groups were that women who re-
ceived M had lower education than women who received
B during pregnancy; the proportion with primary educa-
tion in the Czech Republic was 57.0 versus 40.9% and in
Norway was 83.2 versus 57.6% (Tables 1). However, in
Norway a larger proportion of B women were younger, sin-
gle and smoked tobacco thanMwomen, but the differences
were not significant.
Neonatal outcomes
Tables 3 and 4 show the neonatal outcomes after ex-
posure to M, B or BN in the Czech Republic and
Norway, respectively. In both countries, there were ap-
proximately the same numbers of children exposed to
M and B. Only 20 and 33 of the neonates were ex-
posed to BN in the Czech Republic and Norway, re-
spectively. The mean gestational age was in the
range of 38.3–39.5 weeks in all exposure groups in
both countries. The mean gestational ages tended to
be higher in Norway compared to in the Czech
Republic and higher in B-exposed than in M-exposed
in both countries. When we studied neonates born
at term (≥ 37 weeks of gestation), neonates exposed
to M tended to have slightly lower mean values on
all anthropometric parameters (weight, length and
head circumference) in both countries compared to B
exposure. In addition, in Norway, the proportion of
SGA tended to be higher among M-exposed newborns.
Very few pregnancies resulted in a miscarriage or still-
birth; no stillbirths were observed after B and BN ex-
posure in both countries. The proportion with NAS
was available only in Norway, where 54.7% of the
M-exposed and 53.7% of the B-exposed newborns
had NAS (Table 4). Twenty BN-exposed newborns in
the Czech Republic did not have different neonatal
outcomes than newborns exposed to M or B (Table 3).
Table 5 shows the results of linear and logistic re-
gression analyses of neonatal outcomes comparing B
with M in each country. In all analyses, except the
SGA in the Czech Republic, the β and ORs were in the
direction of more favourable outcomes in B-exposed
newborns, but we observed no significant differences in
neonatal outcomes in either the unadjusted or adjusted
analyses between B- and M-exposed children in both
countries.
Table 1 Socio-economic characteristics of women in opioid maintenance treatment during pregnancy in the Czech Republic.
Methadone (M) Buprenorphine (B) Buprenorphine with naloxone (BN)
n % 95% CI n % 95% CI n % 95% CI
Total number 158 154 21
Age, years
≤ 24 49 31.0 24.0–38.9 42 27.3 20.6–35.1 7 33.3 15.5–56.9
25–29 67 42.4 34.7–50.5 68 44.2 36.2–52.4 4 19.0 6.3–42.6
30–34 32 20.3 14.4–27.5 35 22.7 16.5–30.3 10 47.6 26.4–69.6
≥ 35 10 6.3 3.2–11.7 9 5.8 2.9–11.1 0 0.0 0.0–16.1
Marital status
Not married 126 79.7 72.5–85.6 123 79.9 72.5–85.7 17 81.0 57.4–93.7
Married 28 17.7 12.3–24.8 18 11.7 7.3–18.1 3 14.3 3.8–37.4
Unknown 4 2.5 0.8–6.8 13 8.4 4.8–14.3 1 4.8 0.3–25.9
Education
Primary 90 57.0 48.9–64.7 63 40.9 33.2–49.1 6 28.6 12.2–52.3
Secondary 59 37.3 29.9–45.4 84 54.5 46.3–62.5 11 52.4 30.3–73.6
University 0 0.0 0.0–2.3 1 0.6 0.3–4.1 3 14.3 3.8–37.4
Unknown 9 5.7 2.8–10.9 6 3.9 1.6–8.7 1 4.8 0.3–25.9
Occupation
Unemployed 143 90.5 84.6–94.4 117 76.0 68.3–82.3 14 66.7 43.1–84.5
Employed 11 7.0 3.7–12.4 12 7.8 4.3–13.5 2 9.5 1.7–31.8
Unknown 4 2.5 0.8–6.8 25 16.2 11.1–23.2 5 23.8 9.1–47.6
Use of addictive substances during pregnancy
Alcohol 8 5.1 2.4–10.1 9 5.8 2.9–11.1 0 0.0 0.0–16.1
Smoking 64 40.5 32.9–48.6 60 39.0 31.3–47.1 12 57.1 34.4–77.4
Illicit drugs 58 36.7 29.3–44.8 63 40.9 33.2–49.1 8 38.1 19.0–61.3
Deliveries by multiplicity
Single 152 96.2 91.6–98.5 152 98.7 94.9–99.8 20 95.2 74.1–99.8
Twins and more 6 3.8 1.6–8.5 2 1.3 0.2–5.1 1 4.8 0.3–25.9
CI = confidence interval.
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DISCUSSION
In this observational study of two nation-wide cohorts, we
investigated neonatal outcomes from prenatal exposure to
M and B during pregnancy. Overall, the findings were very
similar in the two countries. The neonatal outcomes in the
B groups were better, albeit not significantly, compared to
the M groups.
Table 2 Socio-economic characteristics of women in opioid maintenance treatment during pregnancy in Norway.
Methadone (M) Buprenorphine (B) Buprenorphine with naloxone (BN)
n % 95% CI n % 95% CI n % 95% CI
Total number 101 99 35
Age, years
≤ 24 5 5.0 1.8–11.7 9 9.1 4.5–17.0 4 11.1 3.7–27.7
25–29 26 25.7 17.8–35.6 28 28.3 19.9–38.4 16 45.7 29.2–63.1
30–34 37 36.6 27.4–46.9 42 42.4 32.7–52.8 10 28.6 15.2–46.5
≥ 35 33 32.7 23.9–42.9 20 20.2 13.1–29.7 5 14.3 5.4–31.0
Marital status
Not married 33 32.7 23.9–42.8 41 41.4 31.7–51.8 17 48.6 31.7–65.7
Married/living with partner 66 65.3 55.2–74.4 58 58.6 48.2–68.3 18 51.4 34.3–68.3
Unknown <4 0 0.0 0.0–3.7 0 0.0 0.0–10.0
Education
Primary 84 83.2 74.1–89.6 57 57.6 47.2–67.3 27 77.1 59.5–89.0
Secondary 13 12.9 7.3–21.4 39 39.4 29.9–49.8 7 20.0 9.1–37.5
University <4 <4 <4
Unknown < 4 <4 <4
Smoking during pregnancy
Yes 64 63.4 53.1–72.6 76 76.8 67.0–84.4 21 60.0 42.2–75.7
Unknown 29 28.7 20.4–38.7 12 12.1 6.7–20.6 6 17.1 7.2–34.3
Deliveries by multiplicity
Single 99 98.0 92.3–99.7 97 98.0 92.2–99.7 33 94.3 79.5–99.0
Twins and more < 4 <4 <4
CI = confidence interval; < 4 denotes fewer than four individuals in the group. Exact numbers are not shown because of regulation from the Registries.
Table 3 Birth outcomes of children of women in opioid maintenance treatment during pregnancy in the Czech Republic; singleton
pregnancy.
Methadone (M) Buprenorphine (B) Buprenorphine with naloxone (BN)
Total number 152 152 20
Gestational agea (weeks), mean (SD) 38.3 (2.6) 38.5 (2.7) 38.5 (1.89)
Birth weightb (g), mean (SD) 3017 (476) 3115 (453) 2897 (450)
Birth lengthb (cm), mean (SD) 48.1 (2.4) 48.6 (2.3) 47.8 (2.3)
Head circumferenceb (cm), mean (SD) 33.8 (1.8) 34.0 (1.6) 33.7 (1.7)
Caesarian sectiona
Elective, n (%; CI) 5 (3.4; 1.3–8.1) 10 (6.6; 3.4–12.1) 3 (15.0; 4.0–38.9)
Acute, n (%; CI) 17 (11.2; 6.8–17.6) 22 (14.5; 9.5–21.3) 1 (5.0; 0.3–26.9)
Stillbirth, n (%; CI) 4 (2.6; 0.8–7.0) 0 (0.0; 0.0–2.4) 0 (0.0; 0.0–16.8)
Preterm birth,a n (%; CI) 25 (16.9; 11.4–24.1) 25 (16.4; 11.1–23.5) 4 (20.0; 6.6–44.3)
Small for gestational agea (SGA), n (%; CI) 19 (12.8; 8.1–19.6) 21 (13.8; 8.9–20.6) 3 (15.0; 4.0–38.9)
Apgar scorea < 7 at 1 min
Yes, n (%; CI) 13 (8.8; 5.0–14.9) 13 (8.6; 4.8–14.5) 2 (10.0; 1.8–33.1)
No, n (%; CI) 135 (91.2; 85.1–95.0) 139 (91.4; 85.5–95.2) 18 (90.0; 66.9–98.2)
Apgar scorea < 7 at 5 min
Yes, n (%; CI) 5 (3.4; 1.3–8.1) 2 (1.3; 0.2–5.2) 0 (0.0; 0.0–16.8)
No, n (%; CI) 143 (96.6; 91.9–98.7) 150 (98.7; 94.8–99.8) 20 (100; 83.2–100)
aSingleton and live births; bsingleton births with gestational age ≥ 37 weeks. CI = confidence interval; SD = standard deviation.
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A systematic review and meta-analysis concluded that
B treatment, compared to M, during pregnancy seemed to
have a lower risk of unfavourable birth outcomes, such as
lower anthropometric data in the unadjusted analyses
[12]. In our study, the B-exposed neonates born at term
had higher birth weight (about 50–100 g) than the
M-exposed group, but these differences were not signifi-
cant. Apart from the statistical significance, the clinical
perspective is also important. To put these observed differ-
ences into context, tobacco smoking reduces birth weight
by approximately 200 g—a difference considered clinically
relevant [35].
Some earlier studies showed a lower NAS prevalence
after exposure to B compared to M [36,37]. We found
no difference in prevalence of NAS in the M and B groups
in the Norwegian sample. This is in line with findings in
an RCT performed by Jones et al. [38], who reported no
significant difference in prevalence of NAS in B and M
groups in the adjusted analysis, although B-exposed
newborns required less intensive NAS treatment than
M-exposed newborns. A systematic review and a
meta-analysis, where the unadjusted results from Jones
et al. were also included, showed differences between M
and B in unadjusted NAS treatment risk. However, the
authors point out that some of these differences may be
due to confounding by indication, and when Jones et al.
performed an adjusted analysis the differences disap-
peared [11]. Indeed, only few studies comparing the
safety of B versus M on the neonate adjust for confound-
ing [39].
A small group of women in the Czech sample received
BN throughout pregnancy. The findings suggest that the
neonatal outcomes in BN-exposed newborns were not dif-
ferent from those who were exposed to B or M. However,
the confidence intervals in the BN group were wide be-
cause of the low number of exposed newborns. Our find-
ings are in line with other studies that have looked at the
safety of BN [16], suggesting that it may be a safe treat-
ment alternative. Note that all existing studies on safety
of BN use very small study samples.
Methodological considerations
As almost all women in OMT are registered in the national
registries, our study had two national cohorts and selection
bias is less of a problem in the current study compared to
previous studies. Further, the size of the sample is a
strength of our study [19], as the majority of previous
Table 4 Birth outcomes of children of women in opioid maintenance treatment during pregnancy in Norway; singleton pregnancy.
Methadone (M) Buprenorphine (B) Buprenorphine with naloxone (BN)
Total number 99 97 33
Gestational ageb (weeks), mean (SD) 38.9 (1.9) 39.2 (2.4) 39.5 (1.7)
Birth weighta (g), mean (SD) 3268 (603) 3333 (437) 3325 (393)
Birth lengtha (cm), mean (SD) 48.7 (3.0) 49.3 (2.0) 49.0 (1.8)
Head circumferencea (cm), mean (SD) 34.4 (1.5) 34.7 (1.6) 34.7 (1.2)
Abortion induced
Yes, n (%; CI) < 4 0 (0.0; 0.0–3.7) < 4
No, n (%; CI) 97 (98.0; 92.2–99.6) 97 (100; 96.3–100) 32 (97.0; 82.5–99.8)
Miscarriage
Yes, n (%; CI) 0 (0.0; 0.0–3.7) < 4 0 (0.0; 0.0–10.6)
No, n (%; CI) 99 (100; 96.3–100) 95 (97.9; 92.0–99.6) 33 (100; 89.4–100)
Caesarian sectionb
Elective, n (%; CI) 10 (10.3; 5.3–18.6) 12 (12.4; 6.8–21.0) < 4
Acute, n (%; CI) 13 (13.4; 7.6–22.2) 9 (9.3; 4.6–17.3) < 4
Stillbirth, n (%; CI) < 4 0 (0.0; 0.0–3.7) 0 (0.0; 0.0–10.6)
Preterm birthb, n (%; CI) 9 (9.3; 4.6–17.3) 5 (5.2; 1.9–12.2) < 4
Small for gestational ageb (SGA), n (%; CI) 10 (10.3; 5.3–18.6) 5 (5.2; 1.9–12.2) 0 (0.0; 0.0–10.6)
Apgar scoreb < 7 at 1 min
Yes, n (%; CI) 7 (7.4; 3.3–15.2) 5 (5.3; 2.0–12.5) < 4
No, n (%; CI) 87 (92.6; 84.8–96.7) 89 (94.7; 87.5–98.0) 31 (96.9; 82.0–99.8)
Apgar scoreb < 7 at 5 min
Yes, n (%; CI) < 4 <4 < 4
No, n (%; CI) 93 (98.9; 93.4–99.9) 93 (97.9; 91.9–99.6) 31 (96.9; 82.0–99.8)
Neonatal abstinence syndromeb
Yes, n (%; CI) 52 (54.7; 44.2–64.9) 51 (53.7; 43.2–63.9) 17 (53.1; 35.0–70.5)
No, n (%; CI) 43 (45.3; 35.1–55.8) 44 (46.3; 36.1–56.8) 15 (46.9; 29.5–65.0)
CI = confidence interval; SD = standard deviation;< 4 denotes fewer than four individuals in the group. Exact numbers are not shown because of regulation
from the Registries. aSingleton births with gestational age ≥ 37 weeks; bsingleton and live births.
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studies on neonatal outcomes included small samples. The
two cohorts represent different parts of Europe and are het-
erogeneous, which may increase the generalizability of the
results.
Using information from the registries reduces the risk
of recall bias, and studies based on data from health reg-
istries can identify and follow more women in OMT over
time than can feasibly be included in clinical samples.
There is an indication that some previous studies may
have been affected by selection bias. For example,
Welle-Strand and colleagues [27] based their study on a
Norwegian clinical sample from 1996 to 2009, while
our register study used data starting from 2004. Approx-
imately two-thirds of the women from the clinical study
were also included in our study. When comparing differ-
ences after M and B exposure in birth weights, not re-
stricted to term pregnancies in any of the studies, these
differed notably. In the study by Welle-Strand and
colleagues the difference was 310 g. In contrast, our
study showed a difference of only 53 g (not shown in
the table, where we show only the birth weight restricted
to term pregnancies). Including an almost complete na-
tional sample of OMT-exposed newborns gave a more pre-
cise mean value of birth weight than did the clinical
sample. The comparison between these studies shows
how selection may give rise to imprecise estimates.
Another possible explanation for the observed differ-
ence in birth weight between the clinical study by Welle-
Strand and our registry study is that confounding by indi-
cation is more of a problem in the clinical study. In Norway,
the criteria for OMT used to be very strict; only the most se-
verely addicted women qualified for OMT. Since then, the
criteria have become less strict, and B is now the recom-
mended treatment for pregnant women who are opioid-
dependent. A great proportion of the women included in
the first years of the Welle-Strand study were probably
Table 5 Lineara and binary logistic regressionb comparing buprenorphine to methadone during pregnancy in the Czech Republic and in
Norway.
Czech Republic Norway
buprenorphine versus methadone (ref.) buprenorphine versus methadone (ref.)
β 95% CI β 95% CI
Gestational agec
Unadjusted 0.16 0.44 to 0.77 0.28 0.33 to 0.90
Adjustedd 0.05 0.68 to 0.59 0.48 0.29 to 1.25
Birth weighte
Unadjusted 98.4 17.2 to 214.0 64.9 91.0 to 220.8
Adjustedd 111.6 10.5 to 233.6 83.1 100.8 to 267.0
Birth lengthe
Unadjusted 0.47 0.12 to 1.06 0.56 0.22 to 1.33
Adjustedd 0.45 0.17 to 1.08 0.47 0.35 to 1.29
Head circumferencee
Unadjusted 0.19 0.31 to 0.69 0.36 0.11 to 0.82
Adjustedd 0.12 0.41 to 0.65 0.57 0.04 to 1.18
OR 95% CI OR 95% CI
Preterm birthc
Unadjusted 0.97 0.53 to 1.78 0.53 0.17 to 1.65
Adjustedd 0.92 0.48 to 1.74 0.73 0.16 to 3.36
SGAc
Unadjusted 1.09 0.56 to 2.12 0.47 0.16 to 1.44
Adjustedd 1.07 0.52 to 2.21 0.83 0.22 to 3.20
Apgar scorec < 7 at 5 min
Unadjusted 0.38 0.07 to 2.00 NA NA
Adjustedd 0.20 0.02 to 2.13 NA NA
Neonatal abstinence syndromec
Unadjusted NA NA 0.96 0.54 to 1.70
Adjustedd NA NA 0.94 0.46 to 1.92
aβ (regression coefficients) from linear regression for gestational age, birth weight, length and head circumference; bodds ratios (ORs) from binary logistic re-
gression of having child birth small for gestation age (SGA), premature birth and Apgar score < 7, neonatal abstinence syndrome (Norway); csingleton and
live births; dadjusted for age, marital status, education, smoking; esingleton births with gestational age ≥ 37weeks. Datawere not available (NA) for the Czech
Republic sample; there were fewer than four individuals in the Norwegian sample.
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more severely addicted than many women in our study, as
they qualified for the strict OMT regimen, and probably re-
ceived M because this was the recommended drug. This
might have induced confounding by indication; newborns
exposed to M probably had more severely addicted mothers
than newborns exposed to B.
BecauseM is a full opioid agonist, pregnantwomenwho
receive M under todays’ recommendations are typically
heavier drug users thanwomen treatedwith the partial ag-
onist B. In the Czech Republic, opioid-dependent women
treated with B are probably also in a better socio-economic
situation compared towomen treatedwithM, as theymust
pay a substantial amount of money for B and M is free of
charge. Adjusting for variables representing socio-
economic status tended to decrease the estimates very
slightly in the Czech Republic. M women in Norway are
probably also heavier drug users than B women. However,
in the Norwegian sample a higher proportion of B women
smoked and were single compared to Mwomen. These fac-
tors may contribute to the slight increase in the estimates
after adjustment. A limitation with using registry data is
that the registries include fewer confounding factors than
do clinical studies. Some important information is under-
reported, or reported in insufficient format in the registries,
e.g. use of alcohol, tobacco and illicit drugs in the Czech
sample [29] and smoking in the Norwegian sample, or
missing, e.g. use of alcohol and illicit drugs in Norwegian
sample. Further, information on nutrition, infections dur-
ing pregnancy and the women’s body mass index (BMI) is
lacking. Missing values in any of the maternal background
variables reduce the sample size in the multivariate regres-
sion analyses and may introduce selection bias. In this
study, this was relevant for the smoking variable.
Only information concerning prescription drugs dis-
pensed to out-patients in Norway is included in NorPD.
Thus, pregnant women receiving OMT in residential treat-
ment were not included in our OMT groups. We assume
this is true for a limited number of cases [26].
Multiple pregnancies have an effect on several neonatal
outcomes. In our study, therefore, only singleton pregnan-
cies were included in the analysis of the neonatal
outcomes.
Even though our samples of pregnant women in OMT
are among the largest to date they are still relatively small,
resulting in difficulty when studying rare outcomes such as
stillbirths andmiscarriages. There was a tendency inmany
of the outcomes in both countries for B to perform better
thanM, but the differenceswere not statistically significant.
If these tendencies are real, larger sample sizes are needed.
CONCLUSION
Although B exposure resulted in more favourable neonatal
outcomes compared to M, the differences were not
significant and the tendencies observed might possibly still
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